Tacrolimus treatment for relapsing-remitting chronic inflammatory demyelinating polyradiculoneuropathy: Two case...

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare autoimmune disorder affecting peripheral nerves.
• Steroid-resistant CIDP presents a significant treatment challenge, necessitating alternative therapeutic strategies.
• Tacrolimus, an immunosuppressant, is explored for its potential efficacy in managing refractory CIDP cases.

Observation:

• Two patients with relapsing-remitting CIDP received tacrolimus-based treatment regimens.
• Clinical assessments monitored motor function recovery and recurrent weakness over a 12-month period.
• Nerve conduction studies and serum tacrolimus levels were systematically recorded throughout the study.

Findings:

• Both patients demonstrated substantial clinical improvement following tacrolimus administration.
• One patient successfully discontinued prednisolone after six months of combined therapy.
• Nerve conduction velocities showed significant recovery, though not fully normalized, indicating a potential lag in electrophysiological compared to clinical recovery.

Implications:

• Tacrolimus presents a viable and safe therapeutic option for patients with steroid-resistant CIDP.
• The findings suggest that tacrolimus can induce significant clinical remission in challenging CIDP cases.
• Further research into long-term efficacy and optimal dosing of tacrolimus in CIDP is warranted.